Yale Cancer Center, Yale School of Medicine, New Haven, CT 06451, USA.
Oncology (Williston Park). 2010 Dec;24(14):1280-8.
Antibody-based targeting of the immune suppressor molecule cytotoxic T-lymphocyte antigen 4 (CTLA-4) with ipilimumab has been studied in metastatic melanoma in a number of clinical trials, including a recent phase III trial. This marks the first randomized clinical trial reporting an overall survival benefit using immune modulation in metastatic melanoma. Along with its therapeutic benefits, ipilimumab presents unique challenges to clinicians; these are related to the monitoring of treatment response and the management of drug-related toxicities. This drug is currently being investigated in various cancers, and its indications are likely to be expanded.
基于抗体的免疫抑制剂分子细胞毒性 T 淋巴细胞相关抗原 4（CTLA-4）的靶向治疗，已在多种临床试验中进行了转移性黑色素瘤的研究，包括最近的一项 III 期临床试验。这标志着首次使用免疫调节治疗转移性黑色素瘤的随机临床试验报告了总体生存获益。除了治疗益处外，伊匹单抗还向临床医生提出了独特的挑战；这些挑战与治疗反应监测和药物相关毒性的管理有关。该药物目前正在各种癌症中进行研究，其适应症可能会扩大。
